Show simple item record

dc.contributor.authorDe Vries, Maaike C.
dc.contributor.authorBrown, David A.
dc.contributor.authorAllen, Mitchell E.
dc.contributor.authorBindoff, Laurence
dc.contributor.authorGorman, Gráinne S.
dc.contributor.authorKaraa, Amel
dc.contributor.authorKeshavan, Nandaki
dc.contributor.authorLamperti, Costanza
dc.contributor.authorMcFarland, Robert
dc.contributor.authorNg, Yi Shiau
dc.contributor.authorO'Callaghan, Mar
dc.contributor.authorPitceathly, Robert D. S.
dc.contributor.authorRahman, Shamima
dc.contributor.authorRussel, Frans G. M.
dc.contributor.authorVarhaug, Kristin Nielsen
dc.contributor.authorSchirris, Tom J. J.
dc.contributor.authorMancuso, Michelangelo
dc.PublishedJournal of Inherited Metabolic Disease. 2020, 43 (4), 800-818.
dc.description.abstractClinical guidance is often sought when prescribing drugs for patients with primary mitochondrial disease. Theoretical considerations concerning drug safety in patients with mitochondrial disease may lead to unnecessary withholding of a drug in a situation of clinical need. The aim of this study was to develop consensus on safe medication use in patients with a primary mitochondrial disease. A panel of 16 experts in mitochondrial medicine, pharmacology, and basic science from six different countries was established. A modified Delphi technique was used to allow the panellists to consider draft recommendations anonymously in two Delphi rounds with predetermined levels of agreement. This process was supported by a review of the available literature and a consensus conference that included the panellists and representatives of patient advocacy groups. A high level of consensus was reached regarding the safety of all 46 reviewed drugs, with the knowledge that the risk of adverse events is influenced both by individual patient risk factors and choice of drug or drug class. This paper details the consensus guidelines of an expert panel and provides an important update of previously established guidelines in safe medication use in patients with primary mitochondrial disease. Specific drugs, drug groups, and clinical or genetic conditions are described separately as they require special attention. It is important to emphasise that consensus‐based information is useful to provide guidance, but that decisions related to drug prescribing should always be tailored to the specific needs and risks of each individual patient. We aim to present what is current knowledge and plan to update this regularly both to include new drugs and to review those currently included.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleSafety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensusen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2020 The Authorsen_US
dc.source.journalJournal of Inherited Metabolic Diseaseen_US
dc.identifier.citationJournal of Inherited Metabolic Disease. 2020, 43(4):800-818en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal